Cargando…

Simeprevir for the treatment of hepatitis C virus infection

Simeprevir (TMC435, Olysio™), a second-generation hepatitis C virus (HCV) protease inhibitor, has been recently approved for the treatment of genotype 1 chronic hepatitis C in combination with pegylated interferon and ribavirin. This molecule has very different characteristics from first-generation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Izquierdo, Laure, Helle, François, François, Catherine, Castelain, Sandrine, Duverlie, Gilles, Brochot, Etienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157399/ https://www.ncbi.nlm.nih.gov/pubmed/25206310 http://dx.doi.org/10.2147/PGPM.S52715

Ejemplares similares

Hepatitis C Virus Resistance to Carbohydrate-Binding Agents
por: Izquierdo, Laure, et al.
Publicado: (2016)

Alginate Hydrogel Protects Encapsulated Hepatic HuH-7 Cells against Hepatitis C Virus and Other Viral Infections
por: Tran, Nhu-Mai, et al.
Publicado: (2014)

Biology of the BKPyV: An Update
por: Helle, Francois, et al.
Publicado: (2017)

Longitudinal Analysis and Comparison of Six Serological Assays up to Eight Months Post-COVID-19 Diagnosis
por: Aubry, Aurélien, et al.
Publicado: (2021)

Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status
por: Helle, François, et al.
Publicado: (2022)

A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies
por: Fournier, Carole, et al.
Publicado: (2007)

Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus
por: Helle, Francois, et al.
Publicado: (2013)

Correction: Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus
por: Helle, Francois, et al.
Publicado: (2019)

BK Polyomavirus Micro-RNAs: Time Course and Clinical Relevance in Kidney Transplant Recipients
por: Demey, Baptiste, et al.
Publicado: (2021)

Comparison of different serological assays for SARS-CoV-2 in real life
por: Brochot, Etienne, et al.
Publicado: (2020)

Intercellular Transmission of Naked Viruses through Extracellular Vesicles: Focus on Polyomaviruses
por: Helle, Francois, et al.
Publicado: (2020)

Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles
por: Oliveira, Catarina, et al.
Publicado: (2017)

Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals
por: Brochot, Etienne, et al.
Publicado: (2020)

Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays
por: Demey, Baptiste, et al.
Publicado: (2020)

The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response
por: Helle, François, et al.
Publicado: (2011)

Indoleamine 2,3-Dioxygenase Is Involved in Interferon Gamma’s Anti-BKPyV Activity in Renal Cells
por: Fiore, Tony, et al.
Publicado: (2020)

Epidemiology and seasonality of acute respiratory infections in hospitalized children over four consecutive years (2012–2016)
por: Fillatre, Adrien, et al.
Publicado: (2018)

BK Polyomavirus Hijacks Extracellular Vesicles for En Bloc Transmission
por: Handala, Lynda, et al.
Publicado: (2020)

BK Polyomavirus bkv-miR-B1-5p: A Stable Micro-RNA to Monitor Active Viral Replication after Kidney Transplantation
por: Demey, Baptiste, et al.
Publicado: (2022)

New treatments for genotype 1 chronic hepatitis C – focus on simeprevir
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
por: Gaetano, John N
Publicado: (2014)

Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection
por: Scott, Jane, et al.
Publicado: (2014)

Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation
por: Khemichian, Saro, et al.
Publicado: (2015)

Enhanced anti-HCV activity of interferon alpha 17 subtype
por: Dubois, Aurelie, et al.
Publicado: (2009)

MicroRNAs and hepatitis C virus: Toward the end of miR-122 supremacy
por: Hoffmann, Thomas Walter, et al.
Publicado: (2012)

Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation
por: Issa, D., et al.
Publicado: (2016)

Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C
por: Sarkar, Souvik, et al.
Publicado: (2015)

Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results
por: Bichoupan, Kian, et al.
Publicado: (2017)

Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir
por: Ascha, Mustafa, et al.
Publicado: (2015)

Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study
por: Alam, Imtiaz, et al.
Publicado: (2016)

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection
por: Zoulim, Fabien, et al.
Publicado: (2018)

Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study
por: Gaeta, Giovanni Battista, et al.
Publicado: (2018)

Photo-induced drug eruption in a patient on combination simeprevir/sofosbuvir for hepatitis C
por: Eyre, Zachary W., et al.
Publicado: (2016)

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin
por: Fevery, Bart, et al.
Publicado: (2016)

Correction: MicroRNAs and hepatitis C virus: toward the end of miR-122 supremacy
por: Hoffmann, Thomas W, et al.
Publicado: (2013)

Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients
por: Watanabe, Takao, et al.
Publicado: (2016)

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study
por: Gane, Edward J., et al.
Publicado: (2017)

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)
por: Lawitz, Eric, et al.
Publicado: (2016)

Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4
por: Abdel-Moneim, Adel, et al.
Publicado: (2019)

Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C
por: Yamagiwa, Satoshi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g0f6gljp2jt7t7e77t0fm1san1